ASMB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 geg. 2024 @ 21:03):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
Dzisiejszy wolumen	15 759.00
Średni wolumen	23 973.00
Kapitalizacja rynkowa	70.56M
EPS	$0 ( 2024-05-02 )
Następna data zysków	( $-3.23 ) 2024-05-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.0780 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-29	White Nicole S	Buy	3 333	Common Stock
2024-04-30	White Nicole S	Sell	1 255	Common Stock
2024-04-29	Okazaki Jason A	Buy	4 166	Common Stock
2024-04-30	Okazaki Jason A	Sell	1 569	Common Stock
2024-04-29	Delaney William E Iv	Buy	3 333	Common Stock

INSIDER POWER
65.29
Last 96 transactions
Buy: 3 858 062 \| Sell: 644 587

Assembly Biosciences Inc Korelacja

10 Najbardziej pozytywne korelacje
TARS	0.932
FLXS	0.929
BUFF	0.925
EYEG	0.925
KBWP	0.925
LDHA	0.924
LVRA	0.922
DXJS	0.921
MSDAU	0.921
LFAC	0.921

10 Najbardziej negatywne korelacje
MYMD	-0.924
TBLT	-0.922
LLNW	-0.921
AGRX	-0.919
IRDM	-0.918
CFRX	-0.916
MSEX	-0.915
AGFY	-0.914
SINT	-0.914
GP	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Assembly Biosciences Inc Finanse

Annual	2023
Przychody:	$7.16M
Zysk brutto:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
Przychody:	$7.16M
Zysk brutto:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
Przychody:	$0
Zysk brutto:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
Przychody:	$6.25M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.